HAVCR2 and acute myeloid leukemia: As metabolic inhibitors are among the promising therapies for AML, and several clinical trials are exploring the effect of TIM-3 blockade in AML patients, we investigated the role of TIM-3 on glucose and lipid metabolism in two AML cell lines.